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Resurrection Men Dig through the Drug Graveyard:
ARYx Revives Problem Blockbuster DrugsOne company’s fiasco can be anoth-
er’s potential fortune, especially if
that fiasco involves a billion-dollar
drug that has been pulled from the
market because of toxic side effects.
Fremont, CA-based ARYx (http://
www.aryx.com/) is in the drug-
resurrection business, reviving other
companies’ failed blockbusters by
reengineering their metabolic path-
ways. ARYx is using a process it
dubs ‘‘retrometabolic drug design’’
to reengineer oral drugs used to treat
blood clots and gastrointestinal and
cardiac problems in order to reduce
or eliminate liver toxicity. Drug-drug
or drug-food interactions can over-
whelm the liver’s cytochrome P-450
oxidase enzyme system, causing
drugs to accumulate in the body to
toxic levels. ARYx ‘‘rehabilitates’’
drugs by working backward, chang-
ing the way they are metabolized and
excreted in the body.
‘‘There is a graveyard for drugs,’’
says Dr. John S. Lazo, Allegheny
Foundation Professor of Pharmacol-
ogy and Director of the Drug Discov-
ery Institute, University of Pittsburgh
School of Medicine. Unexpected
side effects have occasionally led
to blockbuster drugs, such as Via-
gra, Lazo says, but they have also
been the downfall of many good
drugs. Pharmaceutical companies
have, for various reasons, aban-
doned excellent drugs that had
huge potential but were pulled off
the market after FDA approval be-
cause of unexpected side effects.
‘‘The business model of taking
a drug already there and making it
better has clearly been around,’’
Lazo says, citing thalidomide, which
was reapproved, this time to treat
leprosy and is now used for multiple
myeloma. ‘‘Claritin/Clarinex and Pri-
losec/Nexium are examples of drug
reengineering,’’ he added.
Feeling a Bit Liverish?
To find drug candidates suitable for
retrometabolic engineering, ARYx’s
selection committee reviews the lit-
erature for drugs that have largeclinical market potential, are primar-
ily metabolized by the liver (most
drugs are), produce toxic side ef-
fects, and are not constrained by
patents.
ARYx ‘‘rehabilitates’’
drugs by working back-
ward, changing the way
they are metabolized and
excreted in the body.
ARYx chemists then create water
soluble, ‘‘ideal’’ metabolites that
are pharmacologically inert at the
normal dose range of the reference
drug. They chemically attach the
metabolite to the drug molecule.
The upshot should be a new drug
with changed binding interactions
that hopefully will bypass the P-450
bottleneck in the liver and be ex-
creted through the kidneys. The me-
tabolite is different with each pro-
gram, says Pascal Druzgala, ARYx
Chief Scientific Officer. ARYx’s pro-
cess depends on expertise, or ‘‘me-
dicinal chemistry common sense’’
as well as knowledge gained from
the literature about compounds
with no known biological interac-
tions to create the metabolites.
Sometimes, they retroengineer a
known inactive metabolite of a natu-
ral product. They also employ com-
putational methods, although less
frequently.
Metabolites are selected based
on the intended pharmacokinetic
properties of the target compound.
Selection also depends on the size
of the final molecule as a large
drug will probably need a more rad-
ical biotransformation to make it in-
active than a small molecule. For ex-
ample, ARYx chemists designed the
metabolite of ATI-2042 (a potential
drug to target atrial fibrillation) so
that it is negatively charged, Druz-
gala says, impeding its ability to in-teract with cation channels (potas-
sium, sodium, calcium), and so it
therefore would be inactive. They
designed the metabolite for ATI-
5923 (coumadin) to be hydrophilic,
so that it would not interact with
VitK reductase (VitK is a very lipo-
philic substrate for this enzyme).
The company’s researchers may
also tweak the half-life of a molecule
while keeping or improving its prior
pharmacokinetic effectiveness, thus
significantly reducing or eliminating
toxicity by rerouting the metabolic
pathways away from the liver’s P-450
enzyme pathways. Although this was
the rationale for ATI-7505 (a seroto-
nin type 4 agonist) and for ATI-5923,
Druzgala notes, the main strategy for
ATI-2042 was to target tissue es-
terases as the main metabolism
pathwaytoshorten the terminalelim-
ination half-life by making the com-
pound biodegradable in muscles
and organs. ATI-2042 still travels to
the liver but places a substantially
reduced load on the P-450 enzymes.
‘‘From first principles, we’ve
learned a lot about cytochrome
P-450 enzymes in the last ten years,’’
says Dr. John Lazo. ‘‘There has been
a substantial increase of our under-
standing at a genetic level, at a cellu-
lar level, and from a biochemical
level and structural level. Armed
with that information, I think you can
be much more thoughtful in the
construction of the compound that
you are going after. From that stand-
point, I think ARYx’s approach is
appealing.’’
Getting Started in the Resurrection
Business
The company was founded in 1997
by Dr. Peter Milner, a physician with
extensive experience in biotech-
nology, and Pascal Druzgala, a me-
dicinal chemist with a long-standing
interest in ‘‘retrometabolic’’ drug de-
sign. Druzgala had been involved
with similar ideas since 1982 at the
University of Florida. ‘‘Originally,
the soft drug concept, which origi-
nated in several parts of the country
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sity of Florida, was advocating the
use of nonoxidative metabolic sys-
tems in order to safely metabolize
drugs,’’ says Druzgala. In the last
20 years, Druzgala says, more than
ten percent of FDA-approved drugs
were eventually removed from circu-
lation because of toxicity and drug-
drug interactions. The entrepreneurs
saw an opportunity in safety issues,
the underbelly of the drug industry.
They launched the company on the
basis of the intellectual property of
a compound Druzgala invented,
ATI -2042, an analog of amiodarone,
a heart arrhythmia drug that had high
liver toxicity.
For the first several years ARYx
was funded by family and friends
(Milner’s family had been in the
drug business back in England).
The preclinical data and IP of
ATI-2042 convinced MPM Capital in
2002 to lead an investment round of
$25 million with OrbiMed Advisors
and Merlin BioMed. Two years later,
the company received $55 million in
Series D funding led by Nomura
Phase4 Ventures. Currently, ARYx
employs about 55 people and has
20 patents and 22 pending in the
U.S. and another 75 or so foreign
patents, says David Nagler, VP of
Corporate Affairs. In successful re-
vivals, timing is everything. The
company is setting the stage to go
public as its three drug candidates
are now in phase I or II testing.
Side Effects May Include …
ATI-5923, a novel coumadin (warfa-
rin) analog now in phase I trials,
promises to prevent clotting without
endangering patients. Commonly
administered to prevent stroke as-
sociated with blood circulation
problems, ‘‘Warfarin interacts with
pretty much anything, even the
food you eat,’’ says Druzgala, caus-
ing patients to either bleed to death
or suffer stroke if they go off the
drug. The dose effects are unpre-
dictable as they vary with the indi-
vidual. ‘‘ATI-5923 has the same
pharmacology as warfarin,’’ says
Druzgala. ‘‘It basically slows down
the formation of active coagulation
factors, II, VII, IX, and X. The differ-
ence is that our compound, unlike
warfarin, is achiral. It is not a mixture
of isomers. It is not metabolized by
oxidative systems. It is rapidly me-
tabolized by esterase. We havemodified the metabolism so it takes
a different metabolic pathway than
other drugs, so by definition, they
don’t interact.’’
ARYx also has developed ATI-
7505, now in phase II trials. ATI-
7505 is an analog of Propulsid cis-
apride, Janssen Pharmaceutical’s
drug for treating gastrointestinal dis-
eases such as gastroesophageal re-
flux disease (GERD) and diabetic
gastroparesis, which is delayed
emptying of the stomach. Propulsid
commanded a $950 million market
share when it was withdrawn in
2000 because it caused cardiac tox-
icity when administered along with
antifungals or antibiotics.
The Benefits of Hindsight
Large pharmaceutical companies
have tightened up their screening
databases and broadened their pat-
ents after incidents of drugs slipping
through pharmaceutical patents and
being restructured by enterprising
startups. Notably in 1996, Sepracor
transformed Hoechst Marion Rous-
sel Ltd.’s problematic antihistamine
Seldane into a single isomer drug
and then licensed it back to HMR as
Allegra (fexofenadine/pseudoephed-
rine). Seldane was subsequently
banned by the FDA. ‘‘It will be a
matter of being very clever at identi-
fying the best candidates, both from
the chemical standpoint and from an
intellectual property point of view,’’
John Lazo says. ‘‘There are a number
of compounds out there that could
be reengineered for the benefit of
mankind.’’
ARYx is not the only company in
the resurrection business. For exam-
ple, Jazz Pharmaceuticals in Palo
Alto, CA raised $250 million in 2004,
the largest second-round financing
for a drug company to date. Jazz
has no proprietary technology and
does not plan to do R&D but rather
purports to license, improve, de-
velop, and market known com-
pounds for neurological and psychi-
atric disorders. ARYx is also
competing against pharmaceutical
companies themselves, which are
developing other drugs to meet the
same market needs as the ones
they abandoned.
‘‘We do the same old lab bench-
work medicinal chemistry that ev-
erybody else does,’’ says Druzgala,
‘‘and have to establish all the same
preclinical data for the FDA. We be-lieve our advantages are that we
are not attempting to create new val-
idated targets. The big advantage
we have is that we can look at an
old drug with many years of research
and postmarket surveillance.’’
ARYx’s approach bypasses the
long screening stages of drug dis-
covery because it deals with known
compounds brought through FDA
approval—but the revamped drugs
would still have to go through the
most expensive parts of phase III
human clinical testing and resub-
mission to the FDA as well as pass
post-FDA extended clinical use.
Even if a drug has well-character-
ized structure-activity relationships,
redirecting its properties in a com-
plex system, for example, fiddling
with fat versus water solubility, can
cause other unexpected effects,
such as changes in the drug locali-
zation within the body, local toxicity
of a drug, and its rate of uptake and
resulting bioavailability.
The company hopes to offload the
cost of the clinical phase. ‘‘We don’t
expect to be in partnership with the
drug company that made the origi-
nal drug. Our business is based on
entering into a commercial partner-
ship which will work with us under
phase III trials and commercializa-
tion,’’ says David Nagler.
Resurrection is one thing. Re-
demption in the market for refur-
bished drugs known to have a toxic
history is another. It remains an
open question if doctors will be will-
ing to prescribe drugs that have
a bad reputation, even if they have
been revived, reworked, and re-
named.
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